Cargando…
Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
This study aims to explore the relationship between the doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in the real-world setting, so as to preliminarily evaluate the protective effect induced by COVID-19 vaccination. We conducted a test-negative case-control study a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053421/ https://www.ncbi.nlm.nih.gov/pubmed/36992150 http://dx.doi.org/10.3390/vaccines11030566 |
_version_ | 1785015409848614912 |
---|---|
author | Zhang, Dingmei Zhong, Jiayi Xiong, Husheng Li, Yufen Guo, Tong Peng, Bo Fang, Chuanjun Kang, Yan Tan, Jinlin Ma, Yu |
author_facet | Zhang, Dingmei Zhong, Jiayi Xiong, Husheng Li, Yufen Guo, Tong Peng, Bo Fang, Chuanjun Kang, Yan Tan, Jinlin Ma, Yu |
author_sort | Zhang, Dingmei |
collection | PubMed |
description | This study aims to explore the relationship between the doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in the real-world setting, so as to preliminarily evaluate the protective effect induced by COVID-19 vaccination. We conducted a test-negative case-control study and recruited the test-positive cases and test-negative controls in the outbreak caused by Omicron BA.2 in April 2022 in Guangzhou, China. All the participants were 3 years and older. The vaccination status between the case group and the control group was compared in the vaccinated and all participants, respectively, to estimate the immune protection of inactivated COVID-19 vaccines. After adjusting for sex and age, compared with a mere single dose, full vaccination of inactivated COVID-19 vaccines (OR = 0.191, 95% CI: 0.050 to 0.727) and booster vaccination (OR = 0.091, 95% CI: 0.011 to 0.727) had a more superior protective effect. Compared with one dose, the second dose was more effective in males (OR = 0.090), as well as two doses (OR = 0.089) and three doses (OR = 0.090) among individuals aged 18–59. Whereas, when compared with the unvaccinated, one dose (OR = 7.715, 95% CI: 1.904 to 31.254) and three doses (OR = 2.055, 95% CI: 1.162 to 3.635) could contribute to the increased risk of Omicron infection after adjusting for sex and age. Meanwhile, by contrast with unvaccinated individuals, the result of increased risk was also manifested in the first dose in males (OR = 12.400) and one dose (OR = 21.500), two doses (OR = 1.890), and a booster dose (OR = 1.945) in people aged 18–59. In conclusion, the protective effect of full and booster vaccination with inactivated COVID-19 vaccines exceeded the incomplete vaccination, of which three doses were more effective. Nevertheless, vaccination may increase the risk of Omicron infection compared with unvaccinated people. This may result from the transmission traits of BA.2, the particularity and stronger protection awareness of the unvaccinated population, as well as the ADE effect induced by the decrease of antibody titers after a long time of vaccination. It is crucial to explore this issue in depth for the formulation of future COVID-19 vaccination strategies. |
format | Online Article Text |
id | pubmed-10053421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100534212023-03-30 Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study Zhang, Dingmei Zhong, Jiayi Xiong, Husheng Li, Yufen Guo, Tong Peng, Bo Fang, Chuanjun Kang, Yan Tan, Jinlin Ma, Yu Vaccines (Basel) Article This study aims to explore the relationship between the doses of inactivated COVID-19 vaccines received and SARS-CoV-2 Omicron infection in the real-world setting, so as to preliminarily evaluate the protective effect induced by COVID-19 vaccination. We conducted a test-negative case-control study and recruited the test-positive cases and test-negative controls in the outbreak caused by Omicron BA.2 in April 2022 in Guangzhou, China. All the participants were 3 years and older. The vaccination status between the case group and the control group was compared in the vaccinated and all participants, respectively, to estimate the immune protection of inactivated COVID-19 vaccines. After adjusting for sex and age, compared with a mere single dose, full vaccination of inactivated COVID-19 vaccines (OR = 0.191, 95% CI: 0.050 to 0.727) and booster vaccination (OR = 0.091, 95% CI: 0.011 to 0.727) had a more superior protective effect. Compared with one dose, the second dose was more effective in males (OR = 0.090), as well as two doses (OR = 0.089) and three doses (OR = 0.090) among individuals aged 18–59. Whereas, when compared with the unvaccinated, one dose (OR = 7.715, 95% CI: 1.904 to 31.254) and three doses (OR = 2.055, 95% CI: 1.162 to 3.635) could contribute to the increased risk of Omicron infection after adjusting for sex and age. Meanwhile, by contrast with unvaccinated individuals, the result of increased risk was also manifested in the first dose in males (OR = 12.400) and one dose (OR = 21.500), two doses (OR = 1.890), and a booster dose (OR = 1.945) in people aged 18–59. In conclusion, the protective effect of full and booster vaccination with inactivated COVID-19 vaccines exceeded the incomplete vaccination, of which three doses were more effective. Nevertheless, vaccination may increase the risk of Omicron infection compared with unvaccinated people. This may result from the transmission traits of BA.2, the particularity and stronger protection awareness of the unvaccinated population, as well as the ADE effect induced by the decrease of antibody titers after a long time of vaccination. It is crucial to explore this issue in depth for the formulation of future COVID-19 vaccination strategies. MDPI 2023-03-01 /pmc/articles/PMC10053421/ /pubmed/36992150 http://dx.doi.org/10.3390/vaccines11030566 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhang, Dingmei Zhong, Jiayi Xiong, Husheng Li, Yufen Guo, Tong Peng, Bo Fang, Chuanjun Kang, Yan Tan, Jinlin Ma, Yu Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study |
title | Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study |
title_full | Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study |
title_fullStr | Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study |
title_full_unstemmed | Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study |
title_short | Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study |
title_sort | protective effect of inactivated covid-19 vaccines against omicron ba.2 infection in guangzhou: a test-negative case-control real-world study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053421/ https://www.ncbi.nlm.nih.gov/pubmed/36992150 http://dx.doi.org/10.3390/vaccines11030566 |
work_keys_str_mv | AT zhangdingmei protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT zhongjiayi protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT xionghusheng protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT liyufen protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT guotong protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT pengbo protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT fangchuanjun protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT kangyan protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT tanjinlin protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy AT mayu protectiveeffectofinactivatedcovid19vaccinesagainstomicronba2infectioninguangzhouatestnegativecasecontrolrealworldstudy |